Introduction {#sec1-1}
============

Critically ill patients requiring mechanical ventilation frequently need sedatives and analgesics to facilitate their care.\[[@ref1]\] There is an increasing body of evidence showing that protocol-based strategies do not only reduce variation and cost of intensive care medicine, but also improve morbidity and mortality of critically ill patients\[[@ref2]\] . Analgesia and sedation are among these areas where considerable variations exist among practitioners\[[@ref3][@ref4]\]. The concepts of analgesia and sedation in intensive care medicine have changed considerably over the last decade. Deep sedation is no longer the standard practice for most patients as it prolongs weaning from mechanical ventilation and the length of ICU stay and potentially increases morbidity\[[@ref5][@ref6]\] . On the other hand, inadequate sedation can result in anxiety, agitation and in recall of stressful experience in the post-ICU phase\[[@ref7]\] . Therefore, analgesics and sedatives must be carefully titrated to the individual needs\[[@ref8]\] .

Inappropriate sedative use in the intensive-care unit (ICU) is associated with adverse outcomes, including patient discomfort, excessive sedation, longer ICU and hospital stays, an increased incidence of ventilator-associated pneumonia, and greater hospital costs.\[[@ref1]\] The use of propofol or midazolam is recommended\[[@ref1]\] As pain is often the culprit in agitation, an opioid analgesic is recommended, in addition to the previously mentioned agents, to provide adequate analgesia.\[[@ref1]\] However, propofol lacks analgesic properties, and its usage is often limited by hypotension and respiratory depression.\[[@ref1]\] Benzodiazepine is also associated with respiratory depression and the potential for the drug to accumulate, leading to a prolonged recovery period. Dexmedetomidine is a sedative with high affinity for a2-adrenoreceptors\[[@ref9]\] . It sedates via interaction with the locus ceruleus, and has less effect on arousability and patient interaction\[[@ref10][@ref11]\] . In post-surgical patients, dexmedetomidine does not interfere with respiration rate, or arterial oxygenation and carbon dioxide pressure\[[@ref12]\] .The objective of this study was to investigate and evaluate the efficacy and safety of dexmedetomidine in comparison to propofol in the management of sedation for post-operative intensive care unit (ICU) patients, as a sedative agent.

This trial was designed in the Indian population to evaluate the efficacy and tolerability of Dexmedetomidine versus propofol alone in the management of sedation for the period after any major surgery.

Materials and Methods {#sec1-2}
=====================

The objective of this prospective and randomized clinical study was to investigate and evaluate the efficacy and safety of dexmedetomidine in comparison to propofol in the management of sedation for post-operative ICU patients, as a sedative agent.

Sample size was calculated using SAS 9.1.3. The data used to obtain the sample size were derived from a published clinical trial of dexmedetomidine versus propofol when used for intraoperative sedation.\[[@ref13]\] As per the SAS output, 26 patients per group is adequate enough for 90% power or to achieve statistically significant results. Hence, taking into consideration dropouts for this study, a total of 100 patients were included in the study. In our center 30 patients were enrolled, who required the post-operative mechanical ventilation or post-operative sedation, in which 15 patients received Dexmedetomidine and remaining 15 patients received propofol. All patients were treated for the period of 8-24 hours. Data presented here is of only 30 patients done at our centre. Patients undergoing surgery on an inpatient basis, with age from 18 to 70 years of both gender and willing to give the consent were included in the study.

Patients currently being treated or were treated within the last 30 days with alpha-2 agonist and blockers, with central nervous system (CNS), cardio vascular system (CVS), liver, renal problems, history of obstructive sleep apnea, pregnant or lactating females, in whom, propofol would be given for anesthesia were excluded from the study.

After Institutional Ethics Committee approval and a written informed consent from patient or relatives, the patients were enrolled in the study. As per randomization, when each patient had VAS ≥4 and Ramsay sedation score ≤2, they received either dexmedetomidine or propofol and were treated for the period of 24 h. Dexmedetomidine was administrated by a loading dose of injection with 1 mcg/kg over 10 min, followed by a maintenance infusion of 0.2-0.7 mcg/kg/h. The rate of the maintenance infusion was adjusted to achieve the desired level of sedation. Propofol was started at 5 mcg/kg/min (0.3 mg/kg/h). The infusion rate was increased by increments of 5-10 mcg/kg/min (0.3-0.6 mg/kg/h) until the desired level of sedation was achieved. A minimum period of 5 min between adjustments was allowed for the onset of peak drug effect.
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### Cardio respiratory variables {#sec3-1}

Pulse-rate, respiratory rate, blood pressure (Systolic/Diastolic), mean arterial pressure and SPO2; Ramsay sedation scale, VAS, recovery time from sedation and analgesic requirement were noted. Efficacy was assessed to achieve Ramsay score of 2-3 after the surgery as early as possible. RSS is a six-item observer-rated scale to assess the sedation states, in which Score 1 represents anxious or restless or both, 2 co-operative, orientated and tranquil, 3 responding to commands, 4 brisk response to stimulus, 5 sluggish response to stimulus and 6 represents no response to stimulus. VAS is a 0-10 observer-rated scale to assess the pain in which score 0 means no pain and score 10 means severe pain.

The primary efficacy parameter was to evaluate cardio-respiratory end points at equi-sedative doses of Dexmedetomidine and propofol in the ICU. Patient\'s global assessment of pain intensity (0-10 VAS), global assessments of the treatment efficacy by the patient and by the investigator were also noted. If VAS \>4, analgesia (fentanyl) was given.

### Statistics {#sec3-2}

Data were analyzed using Student\'s *t*-test and Chi-square test. The value of *P* \< 0.05 was considered as statistically significant.

Results {#sec1-3}
=======

All the 30 patients completed the study. [Table 1](#T1){ref-type="table"} shows that age and weight were comparable. In Dexmedetomidine group, 6 out of 15 were male. In propofol group, 10 out of 15 were male.

###### 

Demography

![](IJCCM-18-291-g001)
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### Baseline characteristics {#sec3-3}

[Table 2](#T2){ref-type="table"} shows that the mean pulse-rate, respiratory rate, blood pressure between the groups was not statistically significant (*P* \> 0.05). [Table 3](#T3){ref-type="table"} shows comparable laboratory parameters before and after the drug. [Table 4](#T4){ref-type="table"} shows that over the whole study period, the mean RSS was between 2-4 and 2-3 for Dexmedetomidine and propofol groups respectively. There was no statistical significant difference between the two groups throughout the study period. [Table 5](#T5){ref-type="table"} shows the comparison of severity of pain through VAS among the two groups. [Table 6](#T6){ref-type="table"} shows that, over the whole study period, the mean VAS score was maintained between 2-3.5 and 2-3 for dexmedetomidine and propofol groups respectively. However, patients receiving propofol infusions required additional analgesics than patients receiving dexmedetomidine. Fentanyl required in patients receiving propofol infusion was 125 (100-150) mcg. No adverse event was observed in this study.

###### 

Cardio respiratory variables
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###### 

Laboratory parameters
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###### 

Ramsay sedation scale
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###### 

VAS
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###### 

Overall assessment of efficacy by patient
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### Efficacy assessment {#sec3-4}

As shown in [Table 7](#T7){ref-type="table"}, with respect to patients assessment for efficacy, nine patients (i.e., 60%) out of 15 in dexmedetomidine group had shown excellent rating where as none of the patients in propofol group has shown excellent rating, in addition to excellent rating 6 (40%) and 10 (66.67%) patients had given "Good" rating and 0 and 5 (33.33%) patients had given "Poor" rating on treatment with dexmedetomidine and propofol therapy, respectively.

###### 

Overall assessment of efficacy by investigators
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According to investigators, assessment for efficacy represented in ten patients (66.67%) out of 15 in dexmedetomidine group had shown excellent rating as compared to 2 (13.33%) patients in propofol group, whereas 5 (33.33%) and 9 (60%) patients had given "Good" rating and 0 and 4 (26.67%) patients had given "Poor" rating on treatment with dexmedetomidine and propofol therapy, respectively.

### Safety assessment: {#sec3-5}

According to investigators, assessment for safety, 9 (60%) and 3 (20%) patients had given "Excellent" rating, whereas 6 (40%) and 8 (53.33%) patients had given "Good" rating and 0 (0%) and 4 (26.67%) patients had given "Poor" rating upon treatment with dexmedetomidine and propofol, respectively. This is depicted in [Table 8](#T8){ref-type="table"}.

###### 

Overall assessment of safety by investigators
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Discussion {#sec1-4}
==========

This trial is an observational, therapeutic use study investigating the effect of dexmedetomidine versus propofol in patients requiring sedation in intensive care procedures. Sedatives are used in most patients undergoing various surgeries during the post-operative period to reduce anxiety during rewarming and to reduce cardiovascular instability. Articles show that using protocols to guide sedation in various groups of critically ill patients decreases the duration of both mechanical ventilation and ICU stay.\[[@ref1]\]

Dexmedetomidine is as effective as propofol for producing and maintaining adequate short-term sedation of critically ill, mechanically ventilated patients.\[[@ref1]\] The benefits of dexmedetomidine over currently available sedative agents include its lack of respiratory depression and its ability to decrease the need for opioid analgesics.\[[@ref1]\]

The present randomized, open study demonstrated that both infusions of dexmedetomidine and propofol produced sedation, and significant analgesia. Cardiovascular stability and respiratory function were both well maintained. There is a growing interest in the use of α2-adrenoceptor agonists like dexmedetomidine as it has a shorter half-life and has additional analgesic properties and maintains cardio respiratory function.\[[@ref1]\] Finally, antagonists to the effects of α2-adrenoceptor agonists have been described that make quick reversal of sedation an option.\[[@ref14]\] These properties may prove useful for post-operative or intensive care unit sedation. A rise in blood pressure may occur 1 min after the bolus and is attributed to the direct effects of α2-adrenoceptor stimulation of vascular smooth muscle. Dexmedetomidine does not appear to have any direct effects on the heart\[[@ref15]\] . A biphasic cardiovascular response has been described after the application of dexmedetomidine\[[@ref16][@ref17][@ref18]\] . The administration of a bolus of 1 mcg/kg dexmedetomidine initially results in a transient increase of the blood pressure and a reflex decrease in heart rate, especially in younger, healthy patients\[[@ref17]\] . The initial reaction can be explained by the peripheral α2B-adrenoceptor stimulation of vascular smooth muscle and can be attenuated by a slow infusion over 10 or more minutes.

Even at slower infusion rates, however, the increase in mean arterial pressure over the first 10 minutes was shown to be in the range of 7%, with a decrease in heart rate between 16% and 18%\[[@ref18]\] . The initial response lasts for 5 to 10 minutes and is followed by a decrease in blood pressure of approximately 10% to 20% below baseline and a stabilization of the heart rate, also below baseline values; both of these effects are caused by the inhibition of the central sympathetic outflow overriding the direct stimulating effects\[[@ref19]\] . Another possible explanation for the subsequent heart rate decrease is the stimulation of the presynaptic α2-adrenoceptor, leading to a decreased norepinephrine release\[[@ref20]\] . The application of a single high dose of dexmedetomidine reduced norepinephrine release by as much as 92% in young healthy volunteers\[[@ref21]\] . The release of epinephrine is also reduced by the same amount\[[@ref22]\] . This seems to be more important than either central α2-adrenoceptor agonism or non-α adrenaline imidazole- preferring receptors in effecting the change\[[@ref19]\] .

Dexmedetomidine is associated with little respiratory depression. This study confirmed a lack of a clinically significant respiratory effect. Belleville *et al.*\[[@ref23]\] reported that dexmedetomidine could be associated with episodes of obstructive apnea, and this was increasingly common at doses of 1 and 2 mg/kg that were given for 2 minutes and presumably associated with a rapid increase in sedation. Obstructive apnea was not evident in our study. An obstruction resulting in apnea is more likely related to the deep sedation and oral/pharyngeal anatomic events that are common to deep sleep. These properties might prove to be useful in a post-operative setting or in the intensive care unit. Previous studies have reported attenuation of hypertension and tachycardia in response to laryngoscopy and intubation by dexmedetomidine and clonidine.\[[@ref24][@ref25][@ref26]\] Dexmedetomidine has an alpha-2 to alpha-1 receptor selectivity ratio that is 10 times greater than that of clonidine and has a significantly shorter elimination half-life.\[[@ref27]\]

Conclusion {#sec1-5}
==========

In the present study, dexmedetomidine appears to be a safe and acceptable ICU sedative agent when both the clinician\'s and patient\'s perspectives are considered. Depth of sedation is similar to that given by propofol and the extubation time is equally rapid, despite the longer elimination half-life of dexmedetomidine. The cardiovascular respiratory variables of patients sedated with dexmedetomidine are similar to that of patients sedated with equipotent doses of propofol. These properties, combined with the analgesic qualities and lack of respiratory depression seen with dexmedetomidine, have advantages for patients at risk from myocardial ischemia.

In conclusion; dexmedetomidine therapy could be used safely and effectively, in post-operative ICU as sedative and analgesic agent .
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